An Open-label, Dose-escalation, Phase I Clinical Trial to Explore the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPH4336 Tablets in the Treatment of Advanced Solid Tumors
Latest Information Update: 19 Jun 2024
At a glance
- Drugs I 022 (Primary)
- Indications Advanced breast cancer; Male breast cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Shanghai Pharmaceutical Group
Most Recent Events
- 14 Jun 2024 Status changed from active, no longer recruiting to completed.
- 04 Jun 2024 Results assessing the safety, pharmacokinetics (PK) and preliminary efficacy of SPH4336 in patients with advanced solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 02 Apr 2024 Planned End Date changed from 1 Mar 2024 to 1 Jun 2024.